DSwiss Reports 112% Revenue Surge Amid Rising Costs and Declining Net Income in Q1 2025

DSwiss, Inc. (PINK: DQWS) has recently reported its financial results for the quarter ended March 31, 2025. The company operates in the biotech-nutraceutical, beauty supplies, and medical consumables sectors with a focus on high-quality products.

Key Financial Highlights:

• Revenue: $1,001,186, up 112% from $471,377 in Q1 2024.
• Gross Profit: $263,047, down slightly from $269,885 year-over-year, reflecting increased cost of revenue.
• Net Income: $138,736, a decline from $177,665 reported for the same period last year.
• Operating Expenses: Increased to $119,325 from $93,543, impacting profitability.
• Total Assets: $855,176, up from $635,830 as of December 31, 2024.
• Cash Position: Cash and cash equivalents stand at $304,637, almost unchanged from $304,885 a year earlier.

Positive Aspects:

• Significant revenue growth signals strong demand for products and successful market penetration.
• Total assets have increased notably, showcasing potential for growth and expansion.
• Accumulated deficit reduced from $(1,387,930) to $(1,249,194), indicating improvement in financial health.

Negative Aspects:

• Gross profit margin slightly decreased due to higher costs associated with revenue generation.
• Operating expenses rose significantly, which contributed to the decline in net income.
• Current liabilities remain high at $421,313, presenting liquidity concerns.
• Net cash used in operating activities was $(84,751), a notable reversal from the prior year's net cash generated from operations.

DSwiss, Inc. is positioned strongly in the biotech and healthcare sectors, but must address rising operational costs and strive to enhance profitability to sustain its growth trajectory. The company's reliance on a limited number of customers raises potential risks that could impact future revenues.